Effects of inducible overexpression of DNp73α on cancer cell growth and response to treatment in vitro and in vivo

Cell Death and Differentiation

Volumn 12, Issue 7, 2005, Pages 805-814

  Marabese, M ^a   Marchini, S ^a   Sabatino, M A ^a   Polato, F ^a   Vikhanskaya, F ^a   Marrazzo, E ^a   Riccardi, E ^b   Scanziani, E ^b   Broggini, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anticancer agents; In vivo; p53; p73

Indexed keywords

ANTINEOPLASTIC AGENT; DOXYCYCLINE; MESSENGER RNA; PROTEIN P53; PROTEIN P73; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL CLONE; CELL GROWTH; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG RESPONSE; FEMALE; GENE EXPRESSION SYSTEM; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; DNA DAMAGE; DNA-BINDING PROTEINS; DOXORUBICIN; DOXYCYCLINE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HUMANS; MICE; NEOPLASMS; NUCLEAR PROTEINS; PHENOTYPE; TUMOR SUPPRESSOR PROTEINS;

EID: 21744451041     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401622     Document Type: Article

References (36)

1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F and Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819
2. Zhu J, Jiang J, Zhou W and Chen X (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58: 5061-5065
3. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F and Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404: 99-103
4. Moll UM, Erster S and Zaika A (2001) p53, p63 and p73 - solos, alliances and feuds among family members. Biochim. Biophys. Acta 1552: 47-59
5. Melino G, De Laurenzi V and Vousden KH (2002) p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2: 605-615
6. Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G and Wang JY (1999) Structure, function and regulation of p63 and p73. Cell Death Differ. 6: 1146-1153
7. Ueda Y, Hijikata M, Takagi S, Chiba T and Shimotohno K (1999) New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18: 4993-4998
8. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T and Ikawa S (2002) Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 62: 636-641
9. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E and Moll UM (2002) DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196: 765-780
10. Stiewe T, Zimmermann S, Frilling A, Esche H and Putzer BM (2002) Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 62: 3598-3602
11. Nakagawa T, Takahashi M, Ozaki T, Watanabe Ki K, Todo S, Mizuguchi H, Hayakawa T and Nakagawara A (2002) Autoinhibitory regulation of p73 by delta Np73 to modulate cell survival and death through a p73-specific target element within the delta Np73 promoter. Mol. Cell. Biol. 22: 2575-2585
12. Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M and Costanzo A (2002) DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21: 3796-3803
13. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J and Dobbelstein M (2002) p53 induces the expression of its antagonist p73 delta N, establishing an autoregulatory feedback loop. Oncogene 21: 4715-4727
14. Stiewe T, Theseling CC and Putzer BM (2002) Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 277: 14177-14185
15. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF and Khanna KK (2001) Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20: 514-522
16. Maisse C, Munarriz E, Barcaroli D, Melino G and De Laurenzi V (2004) DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur. Cell Death Differ. 11: 685-687
17. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP and Romani M (2002) Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9: 246-251
18. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C and Moll UM (2004) Transdominant {Delta}TAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64: 2449-2460
19. Chi SG, Chang SG, Lee SJ, Lee CH, Kim JI and Park JH (1999) Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res. 59: 2791-2793
20. Ejeskar K, Sjoberg RM, Kogner P and Martinsson T (1999) Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development [In Process Citation]. Int. J. Mol. Med. 3: 585-589
21. Loiseau H, Arsaut J and Demotes-Mainard J (1999) p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci. Lett. 263: 173-176
22. Mai M, Yokomizo A, Qian C, Yang P, Tindall DJ, Smith DI and Liu W (1998) Activation of p73 silent allele in lung cancer. Cancer Res. 58: 2347-2349
23. Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K and Harris CC (1999) Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18: 3415-3421
24. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X and Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387-402
25. Irwin MS (2004) Family feud in Chemosensitvity: p73 and mutant p53. Cell Cycle 3: 319-323
26. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pirnia F, Hugh B, Graber HU, De Laurenzi V, Fey MF, Melino G and Tobler A (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8: 1213-1223
27. Casciano I, Ponzoni M, Cunsolo C, Tonini G and Romani M (1999) Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastoma [in process citation]. Cell Death Differ. 6: 391-393
28. Petrenko O, Zaika A and Moll UM (2003) deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol. Cell. Biol. 23: 5540-5555
29. Kartasheva NN, Lenz-Bauer C, Hartmann O, Schafer H, Eilers M and Dobbelstein M (2003) DeltaNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 22: 8246-8254
30. Liu G, Nozell S, Xiao H and Chen X (2004) DeltaNp73beta is active in transactivation and growth suppression. Mol. Cell. Biol. 24: 487-501
31. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M and Wang JY (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809
32. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104: 263-269
33. Bunz F (2002) Human cell knockouts. Curr. Opin. Oncol. 14: 73-78
34. Vikhanskaya F, Colella G, Valenti M, Parodi S, D'Incalci M and Broggini M (1999) Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin. Cancer Res. 5: 937-941
35. Conforti G, Codegoni AM, Scanziani E, Dolfini E, Dasdia T, Calza M, Caniatti M and Broggini M (1995) Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. Br. J. Cancer 71: 505-511
36. Marabese M, Vikhanskaya F, Rainelli C, Sakai T and Broggini M (2003) DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res. 31: 6624-6632